MedTrace Logo

A Phase I Study to Investigate the Effect of Hepatic Impairment of AZD9550 and AZD6234

NCT07546760 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 28

Last updated 2026-05-05

No results posted yet for this study

Summary

The purpose of this study is to examine the safety and tolerability of AZD6234 and AZD9550 in participants with hepatic impairment and participants with normal hepatic function.

Conditions

  • Hepatic Impairment

Interventions

DRUG

AZD6234

Single subcutaneous dose of AZD6234 in participants from all groups

DRUG

AZD9550

Single subcutaneous dose of AZD9550 in participants from all groups

Sponsors & Collaborators

Study Design

Allocation
NON_RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-03-20
Primary Completion
2027-02-04
Completion
2027-02-04
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07546760 on ClinicalTrials.gov